RNA-Based Molecular Test More Accurately Distinguishes Active C. difficile Infection from Colonization
核心洞察
A novel RNA nucleic acid amplification test can distinguish active Clostridioides difficile (搜索) infection from asymptomatic colonization, addressing a key diagnostic limitation of current tests.
In a study of 239 patient samples, the RNA test achieved 100% accuracy in organism identification, compared with 88.2% for DNA-based testing.
Current antigen tests lack sensitivity, while DNA-based tests cannot differentiate active infection from carriage, leading to underdiagnosis or unnecessary antibiotic treatment.
A novel RNA-based molecular test developed by researchers at the University of Alabama at Birmingham (UAB) can more accurately distinguish patients with active Clostridioides difficile (搜索) (C. diff) infection from those who merely carry the bacteria without active disease, according to a study published in Clinical Infectious Diseases.
Hospital-acquired infections can lead to serious illness or death, especially in patients with weakened immune systems or other critical medical conditions. C. diff is a serious gastrointestinal infection that can progress rapidly and, in severe cases, lead to life-threatening complications if not recognized and treated. However, diagnosis remains challenging because many individuals carry C. diff in their gastrointestinal tract without developing disease, a state known as colonization.
Current diagnostic tests are imperfect and may either fail to identify patients with true infection or detect C. diff in individuals with colonized bacteria. These limitations can lead to missed opportunities for timely treatment in progressing patients or overdiagnosis and unnecessary antibiotic treatment in patients without true C. diff disease. Unnecessary treatment carries its own risks, including disruption of the gut microbiome, adverse drug effects, and additional antibiotic exposure.
Sixto M. Leal Jr., M.D., Ph.D., Jay M. McDonald Endowed Professor and Division Director of Laboratory Medicine, and Kenneth Long, M.D., Ph.D., an assistant professor in the Division of Infectious Diseases and former postdoctoral fellow in Leal's laboratory, conducted the study demonstrating the test's performance. The research, titled "A Novel RNA Nucleic Acid Amplification Test More Accurately Distinguishes Active Clostridioides difficile (搜索) Infection from Colonization," was supported by the UAB Faculty Development Grant Program, the UAB Center for Clinical and Translational Science, and the NIH-funded Antimicrobial Resistance Leadership Group.
"Our research team evaluated the test using 239 patient samples," Leal said. "We found that this test was more accurate and could detect smaller amounts of the bacteria than several commonly used alternative lab tests."
The test's advantage stems from a fundamental biological distinction. Current antigen tests for C. diff lack adequate sensitivity, while current DNA-based nucleic acid amplification tests lack the ability to distinguish active infections from asymptomatic carriage, which can lead to either underdiagnosis or inappropriate treatment, respectively. Unlike DNA, however, RNA is expressed only by metabolically active bacteria, which provides natural advantages to distinguish active infection.
The RNA test outperformed all comparable tests and exhibited higher sensitivity, showing 100% accuracy in organism identification, as compared to 88.2% accuracy when using the DNA test.
"With the current diagnostics we have, we frequently have to use our clinical judgement to determine if a mismatch between a diagnostic result and clinical presentation represents an imperfect test or the potential that something else is going on. A test we could have more confidence in would significantly improve our ability to care for patients at risk for this infection," Long said.
"This new test substantially improves the diagnosis of C. difficile (搜索) infection," said Leal. "Similar approaches may help diagnose other infections caused by spore-forming bacteria and fungi, which we look forward to working on next."